Irvine, California April 5, 2007 -
Masimo, the inventor of Pulse CO-Oximetry and Read-Through Motion and
Low Perfusion pulse oximetry, reported that three new independent
studies, including one presented the recent International
Anesthesiology Research Society (IARS) Clinical & Scientific
Congress in Orlando, concluded that Masimo Acoustic Respiratory
Monitoring technology (ARM) is "at least as accurate as capnometry" and
"significantly more reliable" for monitoring respiration in
spontaneously breathing patients.
Respiration is one of the five vital signs, but clinicians have long
looked for a continuous and noninvasive method of monitoring
respiration that is both clinically accurate, easy to use, and well
tolerated by patients. Current methods of respiration monitoring,
including impedance pneumography with ECG and end-tidal CO2 with capnometry, each have limitations that make them unreliable in certain clinical situations.
In the study released at the recent IARS, conducted by M. R.
Macknet, MD and a team of researchers at Loma Linda University's
Department of Anesthesiology, fifteen pediatric PACU patients were
monitored with Masimo's ARM technology consisting of an adhesive
bioacoustic sensor applied to the patient's neck and connected to a
breathing frequency monitor prototype. In addition, a nasal cannula was
placed, secured with tape, and connected to a capnometer. The study
showed that "premature cannula dislodgement occurred in 14 patients" in
less that 20 minutes, while "in no patient was the bioacoustic sensor
dislodged before the end of the stay in the PACU." 1
"This data shows the relative ease and high incidence of capnometer
cannula dislodgement compared to the new bioacoustic sensor," the
researchers commented. "In clinical settings where continuous and
reliable monitoring of spontaneous respiration is important, the new
bioacoustic sensor provides significantly greater patient connection
time, which should lead to significantly more reliable monitoring of
respiration rate."
In two studies released in January at the 2007 Society for
Technology in Anesthesiology annual meeting, researchers monitored ten
postoperative adult ICU and six pediatric PACU patients in separate
studies with Masimo's ARM technology as well as a nasal cannula
connected to a capnometer. They concluded that Masimo's new bioacoustic
respiratory sensor "demonstrates accuracy for respiratory rate
monitoring as good as capnometry" and that the device "offers multiple
benefits over existing devices and has a potential to improve
monitoring in a general care setting." 2,3
Joe E. Kiani, Founder & CEO of Masimo stated, "We are happy to
see that these initial independent studies reinforce our belief that
Masimo Acoustic Respiratory Monitoring has the potential to be a
breakthrough continuous and noninvasive respiratory rate monitoring
technology that is accurate, reliable and easy to use. Similar to
Masimo SET Read-Through Motion and Low Perfusion pulse oximetry
technology, we recognized that one of the other five primary vital
signs had no available method of giving reliable results and decided to
see if we could come up with a better solution. We are encouraged
that the initial clinical research indicates that the non-obtrusive
nature of the Masimo ARM technology application may help overcome the
problems of conventional respiratory rate monitors without compromising
measurement accuracy."
Masimo expects to combine its Masimo Rainbow SET Read-Through Motion
and Low Perfusion pulse oximetry with Masimo ARM technology as part of
a general floor monitoring solution designed to increase patient safety
and heed the growing call to find ways reduce unnecessary deaths on
general care floors. The combination of these two technologies will
give hospitals a continuous and noninvasive way to accurately monitor a
patient's oxygenation and ventilation during patient-controlled
analgesia, consistent with the new recommendations from the Anesthesia
Patient Safety Foundation (APSF). In addition, the combination of
Masimo Rainbow SET pulse oximetry and Masimo ARM should assist
hospitals in being compliant with new American Society of Anesthesia
(ASA) guidelines for management of patients at risk of obstructive
sleep apnea (OSA) by providing an accurate and reliable combination of
oxygen saturation and respiration rate monitoring.
The technology is currently undergoing additional clinical and
engineering testing and is expected to be introduced at Alpha Sites in
late 2007.
About Masimo
Masimo develops innovative
monitoring technologies that significantly improve patient care-helping
solve "unsolvable" problems. In 1995, the company debuted Read-Through
Motion and Low Perfusion pulse oximetry, known as SET and with it
virtually eliminated false alarms and increased pulse oximetry's
ability to detect life-threatening events. More than 100 independent
clinical studies have confirmed that Masimo SET technology allows
clinicians to accurately monitor blood oxygen saturation in critical
care situations-establishing the technology as the "gold standard"
pulse oximetry and substantially contributing to improved patient
outcomes. In 2005 Masimo introduced Masimo Rainbow SET Pulse
CO-Oximetry, which, for the first time, noninvasively monitors the
level of carbon monoxide and methemoglobin in the blood, allowing early
detection and treatment of potentially life-threatening conditions.
Masimo, founded in 1989, has the mission of "Improving Patient Outcomes
and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites
and Applications." Additional information about Masimo and its products
may be found at www.masimo.com.
1 An improved sensor for
monitoring respiration in pediatric patients. M. Macknet MD, P.
Kimball-Jones MD, R. Applegate II MD, R. Martin MD, M. Allard M.B.Ch.B
FRCA, Loma Linda University, Department of Anesthesiology
2
Accuracy of a novel bioacoustic sensor in adult postoperative
patients. M. Macknet MD, P. Kimball-Jones MD, R. Applegate II MD,
R. Martin MD, M. Allard M.B.Ch.B FRCA, Loma Linda University,
Department of Anesthesiology
3 Accuracy of a novel
bioacoustic sensor in pediatric postoperative patients. Macknet
MD, P. Kimball-Jones MD, R. Applegate II MD, R. Martin MD, M. Allard
M.B.Ch.B FRCA, Loma Linda University, Department of Anesthesiology
Contact:
Tom McCall
Masimo Corporation
949-297-7075
Masimo, SET, Signal Extraction Technology,
Radical, Radical-7, Rad57, APOD, and Improving Outcomes and Reducing
Cost of Care by Taking Noninvasive Monitoring to New Sites and
Applications are registered trademarks of Masimo Corp. ARM, Acoustic
Respiratory Monitoring, BiFi, Rainbow, SpCO, SpMet, SpHb and Pulse
CO-Oximeter are trademarks of Masimo Corp.